AU2002219247A1 - Use of levosimendan for treating erictile dysfunction - Google Patents

Use of levosimendan for treating erictile dysfunction

Info

Publication number
AU2002219247A1
AU2002219247A1 AU2002219247A AU1924702A AU2002219247A1 AU 2002219247 A1 AU2002219247 A1 AU 2002219247A1 AU 2002219247 A AU2002219247 A AU 2002219247A AU 1924702 A AU1924702 A AU 1924702A AU 2002219247 A1 AU2002219247 A1 AU 2002219247A1
Authority
AU
Australia
Prior art keywords
erictile
levosimendan
dysfunction
treating
treating erictile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002219247A
Inventor
Lasse Lehtonen
Jyrki Lilleberg
Pertti Pentikainen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Publication of AU2002219247A1 publication Critical patent/AU2002219247A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002219247A 2000-12-15 2001-12-14 Use of levosimendan for treating erictile dysfunction Abandoned AU2002219247A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20002755A FI20002755A0 (en) 2000-12-15 2000-12-15 Method of therapy for erectile dysfunction
FI20002755 2000-12-15
PCT/FI2001/001101 WO2002047603A2 (en) 2000-12-15 2001-12-14 Use of levosimendan for treating erictile dysfunction

Publications (1)

Publication Number Publication Date
AU2002219247A1 true AU2002219247A1 (en) 2002-06-24

Family

ID=8559724

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002219247A Abandoned AU2002219247A1 (en) 2000-12-15 2001-12-14 Use of levosimendan for treating erictile dysfunction

Country Status (6)

Country Link
US (1) US7115604B2 (en)
EP (1) EP1349551A2 (en)
AU (1) AU2002219247A1 (en)
CA (1) CA2431125C (en)
FI (1) FI20002755A0 (en)
WO (1) WO2002047603A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1252603B (en) * 1990-04-19 1995-06-19 Giorgio Cavallini 2,4-DIAMINO-6 PIPERIDINO PIRIMIDINA-3 TOPICAL OXIDE ON THE GLAND IN THE TREATMENT OF ERECTILE IMPOTENCES
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB2266841A (en) 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
DE4338948A1 (en) 1993-11-15 1995-05-18 Carlen Judith Treating erectile dysfunction without causing side-effects
GB9614098D0 (en) 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
WO1999021558A2 (en) * 1997-10-28 1999-05-06 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
FI974578A (en) 1997-12-19 1999-06-20 Orion Yhtymae Oyj Method of administering levosimendan
FI981473A (en) 1998-06-25 1999-12-26 Orion Yhtymae Oyj A method of treating pulmonary hypertension

Also Published As

Publication number Publication date
WO2002047603A3 (en) 2003-01-30
US7115604B2 (en) 2006-10-03
EP1349551A2 (en) 2003-10-08
FI20002755A0 (en) 2000-12-15
WO2002047603A2 (en) 2002-06-20
CA2431125A1 (en) 2002-06-20
US20040063711A1 (en) 2004-04-01
CA2431125C (en) 2009-06-09

Similar Documents

Publication Publication Date Title
AU2002223827A1 (en) Well treatment
AU2001285159A1 (en) Methods for treating endocrine disorders
AU2001269939A1 (en) Methods for eliminating the formation of biofilm
HK1048073A1 (en) Use of xenon for treating neurointoxications.
AU2001286983A1 (en) Method of treatment
AU3928302A (en) Improved shower apparatus
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2001237939A1 (en) Methods for treating glaucoma
AUPQ761400A0 (en) Removal of toxins from water
AU2001222215A1 (en) Lumbago treating girdle
EG24462A (en) Compounds for treating fundic disaccomodation
AU2001293891A1 (en) New combination for the treatment of asthma
IL154642A0 (en) Treatment of urinary dysfunction
AU2001253836A1 (en) Method of treating cancer
HUP0302430A3 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating urinary incontience
AU2001236929A1 (en) Surface treatment
GB0029468D0 (en) Use of disazo compounds
AU2001262177A1 (en) Method of treatment
AU2000231423A1 (en) Specific therapeutic composition for treating aids
AU2002219247A1 (en) Use of levosimendan for treating erictile dysfunction
AU2001282349A1 (en) Fluid treatment
AU2002228911A1 (en) Methods for inhibiting pain
AU2001281465A1 (en) Treatment of rosacea
AU2001253560A1 (en) Methods of treatment
AU2002212876A1 (en) Method for integrated water treatment